Paxil for Anxiety: How Paroxetine Works, Dosing, and What to Expect
Author:
Blossom Editorial
Paxil is the brand name for paroxetine, a selective serotonin reuptake inhibitor (SSRI) that has been used to treat anxiety disorders since the late 1990s. It carries FDA approval for more anxiety-related conditions than most antidepressants, including generalized anxiety disorder, panic disorder, and social anxiety disorder.
That breadth can be an advantage, though paroxetine also has a reputation for being harder to discontinue than some alternatives. Understanding both sides may help you have a more useful conversation with your prescriber about whether taking Paxil for anxiety makes sense in your situation.
Key Takeaways
Paxil is FDA-approved for three anxiety conditions in adults: generalized anxiety disorder, panic disorder, and social anxiety disorder, alongside depression, OCD, and PTSD. Few antidepressants have as many approvals for anxiety disorders.
Relief tends to build gradually over weeks, not days: Clinical trials measured significant improvement over 8-12 weeks, and longer-term research found that people who stayed on paroxetine relapsed far less often than those switched to placebo. Initial effects may, however, be seen as early as 1-2 weeks.
Stopping generally requires planning: Paroxetine has a short half-life and no long-lasting active byproducts, which can make discontinuation symptoms more likely if it is stopped abruptly. A gradual taper guided by your prescriber is the standard approach.
What is Paxil (Paroxetine)?
Paxil is an SSRI, a class of antidepressants that work by increasing the amount of serotonin available between nerve cells in the brain. Serotonin is a neurotransmitter involved in mood regulation, sleep, appetite, cognition, and anxiety, which is why SSRIs are used for both depression and anxiety.
Paroxetine is available as immediate-release tablets, an oral suspension, and a controlled-release form known as Paxil CR. The generic version is widely available and is what most pharmacies dispense.
Among SSRIs, paroxetine is generally regarded as the most potent serotonin reuptake inhibitor, and it tends to have more anticholinergic activity than its peers. That combination may explain some of its side effect pattern, including dry mouth, sedation, and constipation.
In terms of efficacy, paroxetine is comparable to other antidepressants for major depression. What sets it apart is that it is approved for a wider variety of anxiety disorders than any other antidepressant.
Which Anxiety Disorders is Paxil Approved For?
The FDA has cleared Paxil (paroxetine) for several anxiety-related conditions in adults. Each approval is granted after placebo-controlled trials, which provide a solid evidence base for its effectiveness.
Generalized Anxiety Disorder
Generalized anxiety disorder (GAD) involves persistent, hard-to-control worry across many areas of life, often paired with restlessness, muscle tension, and trouble sleeping. Paxil is approved for GAD in adults.
The supporting evidence includes a double-blind, placebo-controlled trial of 566 adults with GAD. Participants received either paroxetine 20 mg, paroxetine 40 mg, or placebo for eight weeks. Both doses produced significantly greater improvement in anxiety ratings than placebo, with 62% of patients on paroxetine 20 mg and 68% of those on 40 mg showing clinically significant response compared to 46% of placebo users. In addition, the medication was generally well tolerated. This was one of the pivotal FDA registration trials supporting approval.
Panic Disorder
Panic disorder involves recurring, unexpected panic attacks along with ongoing worry about having another one. Paxil was the first SSRI the FDA approved for this condition.
A meta-analysis of randomized controlled trials examined paroxetine’s short-term effect in adults with panic disorder and found it more effective than placebo, with tolerability consistent with the SSRI class overall. Specifically, those on paroxetine saw a significant improvement in the frequency of full panic attacks, improved readings on several anxiety and depression rating scales, as well as better response and remission rates than placebo users.
Social Anxiety Disorder
Social anxiety disorder involves intense fear of being judged or embarrassed in social or performance situations, to a degree that interferes with work, school, or relationships. Paxil holds FDA approval here as well, and it is one of the medications most often studied for this condition. A review of three large clinical trials of paroxetine in 861 patients with social anxiety disorder concluded that 45-66% of them showed statistically significant response over a treatment period of 12 weeks.
Other Conditions Where Paxil is Approved
Besides anxiety disorders, Paxil is also approved for certain conditions that generally involve anxiety, such as post-traumatic stress disorder (PTSD) and obsessive-compulsive disorder (OCD). While not technically classified as anxiety disorders, both conditions can cause significant anxiety and respond to treatment with Paxil.
Post-Traumatic Stress Disorder
Paxil (paroxetine) is one of only two SSRIs with FDA approval for PTSD, the other one being sertraline (Zoloft). Treatment typically addresses intrusive memories, avoidance, hypervigilance, and mood changes following a traumatic event. Medication may work best alongside trauma-focused therapy rather than on its own.
A 2026 Cochrane review found that SSRIs, including paroxetine, improve PTSD symptoms better than placebo and remain first-line medications for PTSD. Across the studies, about 58% of people taking an SSRI improved compared with 35% taking placebo. While paroxetine is an effective treatment for many people, it does not eliminate symptoms for everyone, and a small percentage of patients stop treatment because of side effects.
Obsessive-Compulsive Disorder
Paxil is also approved for OCD, which, although not an anxiety disorder, sits in a related diagnostic category. OCD involves unwanted intrusive thoughts paired with repetitive behaviors or mental rituals aimed at reducing distress.
SSRIs are considered the first-line treatment for OCD and are generally taken at higher doses than for depression. It may also take longer for the full benefits to appear, around 8-12 weeks or longer.
How Long Does Paxil Take to Work for Anxiety?
In some people, physical symptoms may shift within the first couple of weeks. Sleep can improve, and the constant background hum of physical tension may soften slightly. Some people feel more anxious or jittery during the first week or two and may experience insomnia, which are known early effects of SSRIs and often settle.
The meaningful change in worry, avoidance, and overall anxiety severity generally takes longer. In the GAD trial described above, the assessment window was eight weeks, and improvements accumulated across that period. Most prescribers suggest giving a therapeutic dose at least four to six weeks before deciding whether it is working, and closer to eight weeks before concluding it is not.
Longer-term data support staying with the medication once it shows some improvement. In a 24-week relapse prevention study, adults with GAD who responded to paroxetine over eight weeks were randomly assigned to either continue the medication or switch to placebo. About 11% of those who stayed on paroxetine relapsed, compared with about 40% of those switched to placebo. That is a substantial gap, and it may be an argument against stopping early simply because you feel better.
Other long-term clinical studies on Paxil also demonstrated its effectiveness in preventing relapse in patients treated for panic disorder, OCD, and major depression.
Paxil Dosing for Anxiety
Dosing depends on which condition is being treated, and your prescriber may adjust based on response and tolerability. The ranges below reflect the FDA prescribing information.
Typical Starting Doses
Generalized anxiety disorder: commonly started at 20 mg daily, with a usual effective range of 20 mg to 50 mg. There isn’t sufficient evidence of added benefit at doses over 20 mg, though.
Panic disorder: often started lower, around 10 mg daily, then increased gradually because early jitteriness can be more noticeable in this group. The maximum recommended dose is 60 mg. Doses must be increased slowly by 10 mg per week, in case of inadequate response.
Social anxiety disorder: typically started at 20 mg daily. Clinical trials showed effectiveness at doses from 20 mg to 60 mg, though added benefit at doses above 20 mg was not established.
PTSD: typically started at 20 mg daily. Maximum recommended dose is 50 mg per day.
OCD: often requires higher doses than anxiety disorders, with a usual target around 40 mg. Starting dose is 20 mg daily and maximum recommended dose is 60 mg per day. Dose increments must be no more than 10 mg/week.
Dose increases are generally spaced at least one week apart. Paxil CR and Paxil (immediate-release tablets) have different dosing schedules and should only be switched under a prescriber's guidance. The above dose ranges are for Paxil.
Adjustments for Older Adults and Specific Situations
Lower starting doses and lower maximum doses are recommended for older adults and for people with significant kidney or liver impairment. Blood levels of paroxetine can rise more sharply in these groups, so starting conservatively may reduce the chance of side effects that might otherwise lead someone to stop the medication early.
According to the prescribing information, elderly patients and people with severe hepatic (liver) and renal (kidney) impairment must be given a starting dose of no more than 10 mg/day, and the maximum recommended dose is 40 mg daily.
Paxil Side Effects
Side effects are most noticeable in the first few weeks and often ease as your body adjusts. Knowing what is typical makes it easier to distinguish a passing adjustment period from something that needs a change.
Common Side Effects
Nausea, especially in the first week or two
Drowsiness or fatigue
Insomnia
Dry mouth
Sweating
Constipation
Dizziness
Sexual side effects, including reduced libido and difficulty reaching orgasm
Changes in appetite and weight
Paxil tends to be more sedating than some other SSRIs, which can be helpful if anxiety is disrupting your sleep and less helpful if daytime alertness is already a struggle. On the other hand, some people may experience sleep difficulties, such as difficulty falling asleep or staying asleep. Your provider can change the timing of your dose depending on how you respond to the medication.
Paxil is also more often associated with weight gain during long-term treatment than several alternatives, though individual responses vary widely.
Sexual Side Effects
These are common across the SSRI class and are worth raising directly rather than waiting to be asked. Prescribers may consider adjusting the dose, changing the timing, switching medications, or adding a second agent. This is often a solvable problem, and it is one of the most frequent reasons people quietly stop taking antidepressants.
Serious Effects to Report Promptly
Contact your provider or seek urgent care if you notice:
New or worsening thoughts of suicide, particularly in the first weeks or after a dose change
Agitation, tremor, sweating, rapid heart rate, and confusion together, which can signal serotonin syndrome
Unusual bruising or bleeding, since SSRIs can increase bleeding risk, especially alongside blood thinners or NSAIDs
Confusion, weakness, or unsteadiness, which can reflect low sodium levels. This is more common in older adults and people taking diuretics.
Like all antidepressants, Paxil carries a boxed warning about increased risk of suicidal thoughts and behavior in children, adolescents, and young adults during early treatment. This is generally treated as a reason for close monitoring rather than for avoiding treatment.
Stopping Paxil: Why Tapering Matters
This may be the point most worth understanding before starting. Paxil has a relatively short half-life and does not leave behind long-lasting active byproducts. So, if you miss a dose or abruptly stop taking the medication, your blood levels can drop quickly.
The result can be discontinuation symptoms: dizziness, electric shock sensations sometimes described as brain zaps, irritability, anxiety, nausea, vivid dreams, and flu-like feelings. These are not signs of addiction, and they are usually not life-threatening but can be distressing and occasionally severe enough to require restarting or slowing the taper.
Discontinuation symptoms appear to be more common with Paxil (paroxetine) than with longer-acting SSRIs like Prozac (fluoxetine). In fact, Paxil is among the medications with the highest rates of discontinuation symptoms among SSRIs.
The FDA label recommends gradual dose reduction as the standard approach, using stepwise decreases over weeks. Some people need a slower taper than the label suggests, and that is a normal conversation to have. The key point is not to stop on your own.
Remember, across antidepressants, side effects are generally the first to appear, improvement is usually gradual, and stopping them requires a carefully monitored taper in most cases.
How Paxil Compares to Other Anxiety Medications
Paxil (paroxetine) is one of several first-line options for anxiety, and the choice among them often comes down to factors such as side effect profile and drug interactions.
Lexapro (escitalopram) and Zoloft (sertraline) are commonly selected first-line options because they tend to have relatively few drug interactions and milder discontinuation effects. Paxil may be favored in cases where other SSRIs have been ineffective, there are concurrent anxiety disorders, or when sedation would be a welcome effect rather than an unwanted one.
An important caveat on the evidence: a meta-analysis of all paroxetine trials submitted by its manufacturer, including unpublished ones, found the difference between paroxetine and placebo for anxiety to be modest overall, with a larger effect in panic disorder than in generalized anxiety disorder. That analysis has been debated, but it is a useful reminder that antidepressants help many people meaningfully without helping everyone, and that published trials tend to show larger effects than unpublished ones.
Benzodiazepines, such as Xanax (alprazolam) and Ativan (lorazepam), work faster but carry dependence risk, which is why they are usually reserved for short-term or situational use. Non-addictive anxiety medications such as Buspar (buspirone) and Vistaril (hydroxyzine) may be worth considering as alternatives, and coverage for anxiety treatment can vary by plan, so it is worth checking before you start.
Who Should Be Cautious With Paxil
A few situations warrant extra care or a different medication:
Pregnancy or planning pregnancy: Paxil (paroxetine) is generally avoided during pregnancy when possible. The FDA label notes that first-trimester paroxetine exposure has been associated with an increased risk of cardiovascular malformations in epidemiological studies, and it advises considering other options first. This decision involves weighing real risks on both sides and should always involve your obstetric provider.
Current MAOI use: Combining paroxetine with a monoamine oxidase inhibitor is contraindicated because of serotonin syndrome risk. A washout period of at least 14 days is required in either direction.
Certain other medications: Paroxetine strongly inhibits the CYP2D6 liver enzyme, which can raise levels of some heart medications, antipsychotics, and tamoxifen. Bring a full medication and supplement list to your appointment.
Bipolar disorder: Antidepressants can sometimes trigger manic symptoms in people with an underlying bipolar disorder, so screening before starting matters.
When to Talk With a Psychiatric Provider
It is worth reaching out if anxiety is interfering with work, relationships, or sleep, if you are avoiding things you used to do, or if physical symptoms like a racing heart and chest tightness have become a regular part of your week.
If you are already taking Paxil and something is not working - side effects that have not faded after several weeks, no improvement after two months at a therapeutic dose, or a return of symptoms after a period of feeling better - it’s important to discuss this with your provider.
You can also meet a licensed psychiatric provider online from the comfort of your home. Board-certified psychiatrists with Blossom Health can meet you over secure video call to evaluate your symptoms, make a diagnosis, and develop a treatment plan that fits your goals. You can book a virtual appointment with a Blossom Health psychiatric provider covered by in-network insurance and usually be seen within days.
Medical Disclaimer
This article is for informational purposes only and is not a substitute for professional medical advice. Always talk with your physician or another qualified healthcare provider about any questions regarding a medical condition or medication. If you are experiencing a mental health crisis, contact the 988 Suicide and Crisis Lifeline by calling or texting 988.
Sources
U.S. Food and Drug Administration. (2024, November). Paxil (paroxetine) tablets and oral suspension: Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/020031s083,020710s051lbl.pdf
Pae, C.-U., & Patkar, A. A. (2007). Paroxetine: Current status in psychiatry. Expert Review of Neurotherapeutics, 7(2), 107–120. https://www.ovid.com/journals/exneu/abstract/10.1586/14737175.7.2.107~paroxetine-current-status-in-psychiatry
Shrestha P, Fariba KA, Abdijadid S. Paroxetine. [Updated 2023 Jul 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526022/
Chu A, Wadhwa R. Selective Serotonin Reuptake Inhibitors. [Updated 2023 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554406/
Rickels, K., Zaninelli, R., McCafferty, J., Bellew, K., Iyengar, M., & Sheehan, D. (2003). Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. The American journal of psychiatry, 160(4), 749–756. https://pubmed.ncbi.nlm.nih.gov/12668365/
Stocchi, F., Nordera, G., Jokinen, R. H., Lepola, U. M., Hewett, K., Bryson, H., Iyengar, M. K., & Paroxetine Generalized Anxiety Disorder Study Team (2003). Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. The Journal of clinical psychiatry, 64(3), 250–258. https://pubmed.ncbi.nlm.nih.gov/12716265/
Strawn, J. R., Geracioti, L., Rajdev, N., Clemenza, K., & Levine, A. (2018). Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review. Expert opinion on pharmacotherapy, 19(10), 1057–1070. https://pmc.ncbi.nlm.nih.gov/articles/PMC6340395/
Zhang, B., Wang, C., Cui, L., Gao, J., Wang, C., Tan, X., & Fang, S. (2020). Short-Term Efficacy and Tolerability of Paroxetine Versus Placebo for Panic Disorder: A Meta-Analysis of Randomized Controlled Trials. Frontiers in pharmacology, 11, 275. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136560/
Lydiard, R. B., & Bobes, J. (2000). Therapeutic advances: paroxetine for the treatment of social anxiety disorder. Depression and anxiety, 11(3), 99–104. https://pubmed.ncbi.nlm.nih.gov/10875050/
Williams, T., Phillips, N. J., Stein, D. J., & Ipser, J. C. (2026). Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database of Systematic Reviews, 2026(5), CD002795. https://www.cochrane.org/evidence/CD002795_medication-posttraumatic-stress-disorder
Sugarman, M. A., Loree, A. M., Baltes, B. B., Grekin, E. R., & Kirsch, I. (2014). The efficacy of paroxetine and placebo in treating anxiety and depression: a meta-analysis of change on the Hamilton Rating Scales. PloS one, 9(8), e106337. https://pubmed.ncbi.nlm.nih.gov/25162656/
National Institute of Mental Health. (2024, December). Anxiety disorders. U.S. Department of Health and Human Services, National Institutes of Health. https://www.nimh.nih.gov/health/topics/anxiety-disorders
National Institute of Mental Health. (2023). Mental health medications. U.S. Department of Health and Human Services, National Institutes of Health. https://www.nimh.nih.gov/health/topics/mental-health-medications
